Green Valley Announces NMPA Approval Of Oligomannate For Mild To Moderate Alzheimer's Disease

-- Oligomannate , A New Oral Treatment For Mild To Moderate Alzheimer's Disease -- The Only Approved Novel AD Treatment Globally Since 2003SHANGHAI, Nov. 2, 2019 /PRNewswire/ --AShanghai Green Valley Pharmaceuticals (Green Valley) today announced that China'sANational Medical Products AdministrationA(NMPA)Ahas approved Oligomannate (GV-971) asAnew drug for the treatment of "mild to moderate Alzheimer's disease (AD) and improving cognitive function." NMPA granted Oligomannate for fast-track review in November 2018. AIt is the first novel drug approved for Alzheimer's disease globally since 2003. AOligomannate will provide a new treatment option to fight Alzheimer's diseaseAfor patients and is expected to be available in China by the end of 2019.Study Results
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«     2019    »